Chelsea’s FDA Appeal Succeeds; Northera Can Skip Durability Of Effect Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Bogged down since last March by a “complete response” letter, Chelsea has been informed by FDA that a recently completed Phase III trial will be sufficient to back a re-filed NDA for droxidopa in NOH related to Parkinson’s disease.